I'm not going to argue with you whether or not this product will succeed or not. Only time will tell. I'm not going to hold long-term so I don't really care whether or not this product ultimately succeeds. I will say however that some of the points you make in your post are not only outdated but just dead wrong. I'm counting on the HYPE to get me out of this play with a nice big profit ASAP.
Here's the latest company press release that I think pumped the share price at the close. (The stock traded down to 11 3/4 until a late day buying surge brought the close to 12 1/2)
Tuesday March 3, 3:09 pm Eastern Time
Company Press Release
SOURCE: HumanScan Inc.
HumaScan Announces Consumer Education & Media Initiative for
BreastAlert Differential Temperature Sensor and Free Video on Better
Breast Health
Jill Eikenberry begins national educational campaign including network television and exclusive
NY appearance free of charge to the public
CRANFORD, N.J. March 3 /PRNewswire/ -- HumaScan(R) Inc. (Nasdaq: HMSC - news), manufacturer of the
BreastAlert(TM) Differential Temperature Sensor, today announced the beginning of its consumer education and media
initiative with a presentation Wednesday, March 4, 1998, 6-8:30 pm, of ''How I Survived Breast Cancer,'' featuring Jill
Eikenberry and Michael Tucker, Grand Hyatt Hotel, N.Y. Free videos on the importance of early detection are now available
to the public by calling 1/888/HUMASCAN (486-2722.) Free tickets for the NY/Hyatt are available by calling
1-800-752-5588.
As part of the consumer program to raise awareness on the importance of early detection of breast disease, HumaScan Inc.
announced that Ms. Eikenberry is scheduled to appear March 5, 1998 on Good Morning America, as well as a series of
nationally syndicated television and radio shows and a satellite broadcast which features BreastAlert and its role in ongoing
breast monitoring programs. Additional appearances are scheduled in the coming days for Good Day New York, Geraldo,
Bloomberg Business Television and Radio, Fox News, and Entertainment Weekly Radio.
''These appearances provide the ideal forum for women and their families to learn about BreastAlert, especially women under
age 50 whose tumors can actually double in size in less than 80 days,'' said Donald Brounstein, president and chief executive
officer of HumaScan Inc. BreastAlert is a non-invasive, easy to use, low cost adjunctive device to be used by gynecologists,
primary care physicians, and other medical specialists as part of a breast disease monitoring program.
In their New York presentation, which is available at no charge to the public, Ms. Eikenberry and her actor-husband, Michael
Tucker, will discuss the changes to their lives during every aspect of Jill's battle with the disease. Following their program,
members of the audience will be given the opportunity to ask questions of Ms. Eikenberry and Mr. Tucker and may direct
inquiries to panel of leading clinicians and breast cancer experts representing Mount Sinai Medical Center in New York and
Saint Barnabas Health Care System in New Jersey.
Ms. Eikenberry is a breast cancer survivor who was diagnosed with the disease as she was beginning her stint on the long
running television hit show, L.A. Law. Since undergoing successful treatment, she and her husband have dedicated themselves
to a personal campaign of educating women about the need for better breast health.
''We want to help women nationwide learn the value of an ongoing breast monitoring program that includes clinical and breast
self-exams as well as mammography, when indicated. Our message is important: 'The sooner you know, the better your
chances,''' Ms. Eikenberry said.
To obtain a free video about better breast health and early detection or for additional information on the BreastAlert(
Differential Temperature Sensor, call toll free 1-888-HUMASCAN (486-2722) or visit on-line at www.humascan.com.
Headquartered in Cranford, N.J., HumaScan Inc. is a development-stage company that focuses on easy-to-use, low-cost
products and devices that assist physicians and specialists in the diagnosis and early detection of disease.
This release contains forward-looking information including statements regarding the positive impact that this adjunctive
product may have in assisting physicians in early detection of breast disease in women of all ages. Additional information on
factors that could potentially affect the company's financial results may be found in the HumaScan Inc. filings with the Security
and Exchange Commission.
To receive additional information on HumaScan Inc., via fax, at no charge, dial 1-800-PRO-INFO and enter code HMSC. |
